New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 24, 2019 - The FDA announced the approval of Eli Lilly’s Baqsimi (glucagon) nasal powder, for the treatment of severe hypoglycemia in patients with diabetes ages 4 years and above.
Download PDF
Return to publications
